Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.

District Court, W.D. Texas·Decided August 4, 2021·No. 1:20-cv-00783·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

HOMELAND INSURANCE COMPANY OF § NEW YORK, § § Plaintiff / Counter Defendant, § § v. § 1:20-CV-783-RP § CLINICAL PATHOLOGY LABORATORIES, § INC, SONIC HEALTHCARE USA, INC., § MEDLAB PATHOLOGY, SONIC § HEALTHCARE (IRELAND), LIMITED, § and SONIC HEALTHCARE, LIMITED, § § Defendants / Counter Plaintiffs. §

AMENDED ORDER Before the Court is Defendants Clinical Pathology Laboratories, Inc. (“CPL”), Sonic Healthcare USA, Inc. (“Sonic USA”), MedLab Pathology (“MedLab”), Sonic Healthcare (Ireland) Ltd. (“Sonic Ireland”), and Sonic Healthcare Ltd.’s (“Sonic”) (together, “Defendants”) Motion to Dismiss Plaintiff Homeland Insurance Company’s (“Homeland”) Amended Complaint, (Dkt. 21). (Dkt. 24). Homeland filed a response, (Dkt. 25), and Defendants filed a reply, (Dkt. 26). Having considered the parties’ submissions, the record, and the applicable law, the Court will grant in part and deny in part the motion.1 I. BACKGROUND This case is about an insurance coverage dispute. Homeland provides insurance coverage to Defendants, who work together to provide cervical cytology laboratory screening services to detect

1 This order amends the Court’s previous order, (Dkt. 28), after granting in part Defendants’ motion for reconsideration as to Homeland’s negligent misrepresentation claim. (Mot., Dkt. 36, Order, Dkt. 54). cervical cancer. (Am. Compl., Dkt. 21, at 2). CPL and Sonic USA are located in the United States, while MedLab, Sonic Ireland, and Sonic are located outside the United States. (Id. at 2). Around March 2010, as part of a national program in Ireland called CervicalCheck, the National Screening Service (“NSS”)2 of Ireland entered into contracts with Sonic Ireland and MedLab to provide screening services for cervical cancer. (Id. at 6). The contracts identified CPL, in Austin, Texas as the laboratory that that would read the cancer screening slides. (Id.; Resp., Dkt. 25,

at 5; Mot. Dismiss, Dkt. 24, at 7). Also in 2010, CervicalCheck began an audit process called Cancer Audit Reviews (“CARs”) that reviewed women’s screening history after they developed cervical cancer, to determine whether any slides in previous screenings had been misread. (Am. Compl., Dkt. 21, at 6–7). Around 2016, the NSS changed its protocol to require CARs results where slides had been misread to be reported to the patients’ physicians. (Id. at 7–8). Before 2016, Homeland insured CPL, Sonic USA, and Sonic only for claims made inside the United States. (Id. at 10). Around 2015 and 2016, Homeland informed CPL and Defendants’ broker that there was no insurance coverage for a claim about misread slides because the claim was made outside the United States. (Id. at 10–12). Later in 2016, Defendants sought to expand coverage to (1) include claims made outside the U.S. against CPL and Sonic USA, and (2) include MedLab and Sonic Ireland as additional named insureds limited to coverage for cervical cytology screening services provided from August 2010 to June 2013 for claims made in the U.S. (Id. at 12).

Homeland agreed to the requested expanded coverage for the 2016–17 insurance policy (“2016 Policy”), allegedly conditioned upon a July 27, 2016 letter (“2016 Letter”) provided by Stephen Shumpert, CPL’s President and Director and Sonic USA’s Chief Executive Director and

2 The NSS was initially the National Cancer Screening Service (“NCSS”), until it became the NSS in 2014. (Am. Compl., Dkt. 21, at 5). For simplicity, the Court will refer to it as the NSS. Director, stating that, on behalf of the insureds, they were not aware of any potential claims against the insureds. (Id. at 13; 2016 Letter, Dkt. 21-1). Homeland alleges that the assurances in this letter were false, because at least some of the Defendants were aware of potential claims based on misread slides. (Am. Compl., Dkt. 21, at 15). Defendants’ insurance coverage was later extended to 2017– 2018 (“2017 Policy”). (Am. Compl., Dkt. 21, at 14). In 2018, a lawsuit was filed on behalf of “Ms. S” based on a misread slide (the “Ms. S

claim”). (Id. at 24). CPL settled this matter in October 2019. (Id.). In May 2020, CPL sought reimbursement from Homeland for this claim, alleging that the claim is covered under the 2017 Policy. (Id. at 25). In July 2020, Homeland denied the claim. (Id.). Based on these allegations, Homeland asserts several causes of action. Homeland brings (1) a claim for declaratory judgment that there is no coverage for the Ms. S claim under the 2017 Policy; (2) a negligent misrepresentation claim based on the 2016 Letter seeking attorney’s fees and damages for the amount of coverage due on the Ms. S claim; (3) a breach of warranty claim based on the 2016 Letter; and (4) a claim for reformation of the 2017 Policy to reflect that the 2016 Letter was meant to exclude certain claims from coverage. (Id. at 40–43). Defendants filed a motion to dismiss the defendants outside the United States for lack of personal jurisdiction under Federal Rule of Civil Procedure 12(b)(2) and to dismiss each of the claims against Defendants under Rule 12(b)(6) for failure to state a claim. (Mot. Dismiss, Dkt. 24).

The Court will consider each issue in turn. II. LEGAL STANDARD A. Rule 12(b)(2) The Federal Rules of Civil Procedure allow a defendant to assert lack of personal jurisdiction as a defense to suit. Fed. R. Civ. P. 12(b)(2). “When a nonresident defendant presents a motion to dismiss for lack of personal jurisdiction, the plaintiff bears the burden of establishing the district court’s jurisdiction over the nonresident.” Stuart v. Spademan, 772 F.2d 1185, 1192 (5th Cir. 1985). When, as here, a court considers a motion to dismiss for lack of personal jurisdiction without holding an evidentiary hearing, the plaintiff need only present a prima facie case that personal jurisdiction is proper. Walk Haydel & Assocs., Inc. v. Coastal Power Prod. Co., 517 F.3d 235, 241 (5th Cir. 2008). Courts may consider the contents of the record, including affidavits or other recognized methods of discovery, in deciding whether to exercise specific jurisdiction. Stuart v. Spademan, 772

Free access — add to your briefcase to read the full text and ask questions with AI

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., (W.D. Tex. 2021).

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc. (Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Latshaw v. Johnston
167 F.3d 208 (Fifth Circuit, 1999)
C.P. Interests, Inc. v. California Pools, Inc.
238 F.3d 690 (Fifth Circuit, 2001)
Nuovo Pignone S P A v. Storman Asia MV
310 F.3d 374 (Fifth Circuit, 2002)
Mayo v. Hartford Life Insurance
354 F.3d 400 (Fifth Circuit, 2004)
Freudensprung v. Offshore Technical Services, Inc.
379 F.3d 327 (Fifth Circuit, 2004)
Causey v. Sewell Cadillac-Chevrolet, Inc.
394 F.3d 285 (Fifth Circuit, 2004)
Seiferth v. Helicopteros Atuneros, Inc.
472 F.3d 266 (Fifth Circuit, 2006)
Cuvillier v. Taylor
503 F.3d 397 (Fifth Circuit, 2007)
Dorsey v. Portfolio Equities, Inc.
540 F.3d 333 (Fifth Circuit, 2008)
Harrington v. State Farm Fire & Casualty Co.
563 F.3d 141 (Fifth Circuit, 2009)
McFadin v. Gerber
587 F.3d 753 (Fifth Circuit, 2009)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Turner v. Pleasant
663 F.3d 770 (Fifth Circuit, 2011)
In Re Katrina Canal Breaches Litigation
495 F.3d 191 (Fifth Circuit, 2007)